A large asset of at least $3.9 billion, which is required to meet the World Health Organisation’s (WHO); aims for the elimination of the Hepatitis C Virus (HCV) in Pakistan. According to the University of Bristol-led research in The Lancet Global Health, the idea is to deliver huge benefits in terms of lives saved and reduced ill health.
To meet the WHO target, Pakistan should get free of Hepatitis C, as it has the highest rates, around 10 percent of global infections. DAAs, new Direct-Acting Antivirals are supremely efficient in curing this HCV infection. It ended up in WHO putting forward a strategy that is to eliminate HCV by 2030. Though the targets have been reduced by 80 percent, still there is a lack of information on how to eliminate the core of it in lower-middle-income countries.
In the association between the University of Bristol, Pakistan HCV Task Force, US Centers for Disease Control and Prevention, mathematical modeling has been utilized to see the screening and treatment required for eliminating the targets and analyzing the estimated cost.
This study brought forward that to achieve the purpose by 2030, around 36 million people will be needed to be screened and 660,000 to be treated annually. To fight with the new infections, regular screening will be done. In order to achieve WHO target, it would mean to prevent 5.8 million new infections.
Dr. Aaron Lim, infectious disease mathematical modeler and chief author from the University of Bristol, said: “Our modeling suggests that Pakistan’s HCV epidemic is on the rise, with around 700,000 new infections occurring each year, rapidly adding to the current 7.5 million people, or about four percent of the population, who are infected with HCV. The situation is expected to get worse if interventions are not scaled up. With fewer than 14 percent of infected people aware of their infection status, and even fewer having been treated, it is clear